Boston Therapeutics, Inc. Requests an IND Meeting With the FDA for PAZ320 to Reduce Postprandial Hyperglycemia in Type 2 Diabetes
4/11/2013 11:00:37 AM
More...
|
Boston Therapeutics, Inc. Featured in Four Publications
4/8/2013 9:25:57 AM
More...
|
Boston Therapeutics, Inc. Reports Full Year 2012 Financial Results
4/5/2013 9:14:44 AM
More...
|
Boston Therapeutics, Inc. Strategically Positioned to Focus Its Pipeline on Commercializing Pharmaceutical Drugs to Treat Diabetes and Inflammatory Disease: to Accelerate Commercialization of PAZ320 & IPOXYN™
3/27/2013 10:21:18 AM
More...
|
Boston Therapeutics, Inc. Appoints Peter Sheehan, M.D. as Medical Director
3/12/2013 9:02:59 AM
More...
|
Boston Therapeutics, Inc. Reports Positive Phase ll Clinical Trial Results of PAZ320 in Patients With Type 2 Diabetes
2/26/2013 9:20:47 AM
More...
|
Boston Therapeutics, Inc. Announces Clinical Study Final Results Indicate That SUGARDOWN® Reduced the Post-Meal Elevation of Blood Glucose by Up to 61% in Healthy Volunteers
1/28/2013 8:49:50 AM
More...
|
Boston Therapeutics, Inc. Approved in France to Initiate a Clinical Trial With SUGARDOWN® in Patients With Type II Diabetes
12/19/2012 10:12:16 AM
More...
|
Boston Therapeutics, Inc. to Present Corporate Update at the SeeThruEquity Smallcap & Microcap Investor Summit
11/29/2012 9:17:34 AM
More...
|
Boston Therapeutics, Inc. Wins FDA Approval to File an Abbreviated New Drug Application for PAZAMET™ to Treat Diabetes
10/4/2012 8:43:36 AM
More...
|
|